Publications [#63295] of Mark W. Dewhirst

Papers Published

1. Laskowitz, K.T. and Elion, G.B. and Dewhirst, M.W. and Griffith, O.W. and Savina, P.M. and Blum, M.R. and Prescott, D.M. and Bigner, D.D. and Friedman, H.S., Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft, Radiat. Res. (USA), vol. 129 no. 2 (1992), pp. 218 - 23
   (last updated on 2007/04/14)

   Abstract:
   The effects of regional hyperthermia (42°C for 70 min) on the antitumor activity of melphalan were examined in athymic mice bearing melphalan-resistant human rhabdomyosarcoma (TE-671 MR) xenografts growing in the right hind limb, and results were compared with similar studies of melphalan-sensitive (TE-671) parent xenografts. Melphalan alone at a dose of 36 mg/m² (0.5 of the 10% lethal dose) produced growth delays of 4.1 to 10.2 days in TE-671 MR xenografts and 21.8 to 28.7 days in TE-671, respectively. Hyperthermia alone produced growth delays of 0.9 days in TE-671 MR xenografts and 0.8 days in TE-671. Combination therapy with melphalan and hyperthermia produced growth delays of 7.2 to 13.3 days in TE-671 MR xenografts and 34.3 to 42.8 days in TE-671, respectively, representing a mean thermal enhancement ratio of 1.7 in TE-671 MR and 1.5 in TE-671. Combination therapy with melphalan plus regional hyperthermia offers promise for treatment of melphalan-resistant neoplasms

   Keywords:
   biothermics;muscle;